U.S. Cancer And Tumor Biomarker-based Assay Market Size & Outlook
Related Markets
U.S. cancer and tumor biomarker-based assay market highlights
- The U.S. cancer and tumor biomarker-based assay market generated a revenue of USD 3,837.7 million in 2024 and is expected to reach USD 9,651.7 million by 2033.
- The U.S. market is expected to grow at a CAGR of 10% from 2025 to 2033.
- In terms of segment, breast cancer was the largest revenue generating cancer type in 2024.
- Lung Cancer is the most lucrative cancer type segment registering the fastest growth during the forecast period.
Cancer and tumor biomarker-based assay market data book summary
| Market revenue in 2024 | USD 3,837.7 million |
| Market revenue in 2033 | USD 9,651.7 million |
| Growth rate | 10% (CAGR from 2025 to 2033) |
| Largest segment | Breast cancer |
| Fastest growing segment | Lung Cancer |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer |
Other key industry trends
- In terms of revenue, U.S. accounted for 35.0% of the global cancer and tumor biomarker-based assay market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. cancer and tumor biomarker-based assay market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 735.1 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer and Tumor Biomarker-based Assay Market Scope
Cancer and Tumor Biomarker-based Assay Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Hologic, Inc. | View profile | - | - | - |
| Abbott | View profile | - | - | - |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Illumina, Inc. | View profile | - | - | - |
| Sysmex Corp | View profile | 10448 | 1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, Japan, 6510073 | http://www.sysmex.co.jp |
| Exact Sciences Corp | View profile | 6600 | 5505 Endeavor Lane, Madison, WI, United States, 53719 | https://www.exactsciences.com |
| Guardant Health Inc | View profile | 1779 | 3100 Hanover Street, Palo Alto, CA, United States, 94304 | https://www.guardanthealth.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Bio-Rad Laboratories Inc | View profile | 8030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | https://www.bio-rad.com |
| Agilent Technologies Inc | View profile | 17700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | https://www.agilent.com |
| Quest Diagnostics Inc | View profile | 48000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | https://www.questdiagnostics.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| BioMerieux SA | View profile | 13982 | Marcy l’Etoile, Lyon, France, 69280 | http://www.biomerieux.com |
U.S. cancer and tumor biomarker-based assay market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer and tumor biomarker-based assay market will help companies and investors design strategic landscapes.
Breast cancer was the largest segment with a revenue share of 27.64% in 2024. Horizon Databook has segmented the U.S. cancer and tumor biomarker-based assay market based on breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to U.S. cancer and tumor biomarker-based assay market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. cancer and tumor biomarker-based assay market databook
-
Our clientele includes a mix of cancer and tumor biomarker-based assay market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cancer and tumor biomarker-based assay market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cancer and tumor biomarker-based assay market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
US Cancer Type - Cancer And Tumor Biomarker-based Assay Market size, 2024 - 2033 (US$M)
U.S. Cancer and Tumor Biomarker-based Assay Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
